The primary focus for AbbVie on December 27, 2025, centers on the anticipated drug-pricing deal with the U.S. government. Reports from December 22 and December 20 indicated AbbVie is among the few major pharmaceutical companies expected to finalize "Most Favored Nation"-style agreements "soon after the holidays." Investors are closely watching for this announcement as it could reduce policy uncertainty, though it also raises questions about pricing flexibility for future product launches, particularly for its immunology and neuroscience portfolio.